리가켐바이오

141080KOSDAQ자연과학 및 공학 연구개발업

42.9 / 100

Reference Date: 2026-06-10

Financial Score10.5 / 40

News Sentiment17.4 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Plunged 29.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Ligacem Bio is a biopharmaceutical company specializing in next-generation ADC (Antibody-Drug Conjugate) technology through its proprietary platform 'ConjuALL', targeting unmet medical needs in oncology. The company has secured multiple technology transfer agreements with global pharmaceutical firms, including Fosun Pharma and Janssen, and reported revenue of approximately 10.54 billion KRW in 2024. It also operates a medical supply business, contributing to its diversified revenue streams.

Number of Employees

180people

Average Salary

157.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

8.76Industry Average 3.240.0Point

2.7x industry avg (risky)

ROE

-15.82Industry Average -32.093.5Point

Well below industry avg

Debt Ratio

18.41Industry Average 7.310.0Point

2.5x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲140.6% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼167.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -18.0% (improving, 3yr)

Detailed News Sentiment

29 totalPositive 14Neutral 8Negative 7Average Sentiment Score 69.5

Neutral
코스피·코스닥 매수사이드카 발동…반도체·장비주 강세
리가켐바이오 관련 직접적인 영향 없이 전반적인 반도체 및 장비주 상승에 따른 시장 동향 반영.
Positive
빅파마 ADC 쇼핑 시작되나…리가켐바이오 기술수출 기대감 커진다[Why...
리가켐바이오의 ADC 기술 수출 기대감이 증가하여 긍정적인 시장 반응을 이끌고 있다.
Positive
"주가 낙폭 과도" 지적 속 알테오젠·리가켐·에이비엘 하반기 모멘텀.....
리가켐바이오를 포함한 바이오 플랫폼 기업들이 내재가치를 강조하며 하반기 반등 기대감을 높이고 있다.

Detailed Momentum

52-week position3.0Point

52w lower range (21%)

Current 128,000Won52-week high 213,50052-week low 104,200

1-month return0.0Point

1m -29.94% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]2026-06-01
Neutral분기보고서 (2026.03)2026-05-15
Neutral투자판단관련주요경영사항(임상시험계획승인신청등결정) (CLDN18.2 항체-약물 접합체 (ADC) LCB02A의 제 1/2상 임상시험의 미국 임상시험계획(IND) 승인)2026-05-14
Neutral[기재정정]기업설명회(IR)개최2026-05-14
Neutral기업설명회(IR)개최2026-05-14